Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation

NCT: NCT06364215 · TERMINATED

NCT IDNCT06364215
StatusTERMINATED
Start Date2024-10-08
Completion2025-11-16

Brief Summary

The purpose of this study is to compare the efficacy and safety between pulmonary vein isolation (PVI) alone versus PVI with left atrial (LA) posterior wall isolation (PWI) using pulsed-field ablation (PFA) in the treatment of patients with paroxysmal atrial fibrillation (PAF).

Frequently Asked Questions

What is Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation?

Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation is a clinical trial registered under NCT06364215. Current status: TERMINATED.

What is the status of NCT06364215?

The current status of NCT06364215 (Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation) is: TERMINATED.

When did Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation start?

Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation started on 2024-10-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑